SG11201407917PA - Highly efficient method for establishing artificial pluripotent stem cell - Google Patents

Highly efficient method for establishing artificial pluripotent stem cell

Info

Publication number
SG11201407917PA
SG11201407917PA SG11201407917PA SG11201407917PA SG11201407917PA SG 11201407917P A SG11201407917P A SG 11201407917PA SG 11201407917P A SG11201407917P A SG 11201407917PA SG 11201407917P A SG11201407917P A SG 11201407917PA SG 11201407917P A SG11201407917P A SG 11201407917PA
Authority
SG
Singapore
Prior art keywords
episomal vector
ebna
kyoto
cell
ips cell
Prior art date
Application number
SG11201407917PA
Inventor
Shinya Yamanaka
Keisuke Okita
Original Assignee
Univ Kyoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kyoto filed Critical Univ Kyoto
Publication of SG11201407917PA publication Critical patent/SG11201407917PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/608—Lin28
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

(i2) mwu ft iz s-5 iv x m £ titz s issaj n d9) mm IHMMi _ (41) SI5S4>!H B 2013^11 £ 28 0(28.11.2013) W j\"^| PCT (10) WO 2013/176233 A1 (51) C12N 5/10 ( 2006.01) (21) (22) (25) (26) 4>§fl(£> S lp: C12N15/113 (2010.01) PCT/JP2013/064409 2013 ^ 5 M 23 0(23.05.2013) (84) (30) fiBfefix — £: 61/650,694 2012 ^ 5 ^ 23 0(23.05.2012) US (71) ttiJiA: A^BA^KYOTOJJNIVER- SITY) [JP/JP]; T6068501 sfPJttSfPTfTSsI* • H ^BT 3 6 #±fe 1 Kyoto (JP). (72) ^ BJ # : UU cf 3 # ^ (YAMANAKA, Shiny a); T 6068501 5liRJ#5li5rp£5l|ESBa^Prr3 6ftt 1 AjjifRA^fa _Kyoto (JP). #ea ^j>(OKITA, Keisuke); T 6068501 rfT£ > 5iE^Ba^E3T3 6#±fe 1 A«f|5A Kyoto (JP). _ U^m (74) ft HA: 1ft S — (TAKASHIMA, Hajime); T — 5410044 AlKJttAIKrfT^^EtfcJIBTeaTg 1 # 5.2(a)) m BJ ?£ S H M ^ 85 if J I/ Osaka (JP). (8i) Jt^ia (^©fti^psy, £-ca>ffi3ia>@Affi 11^ nlfb): AE, AL, AM, AG, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. V&tf nlfb): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), 3- — V T (AM, AZ, BY, KG, KZ, RU, TJ, TM), 3 — • V / ^ (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). 21 ^(3)) (£>5JIJill(£> B|5^<t LTi LfciEJU U X h m CJ i> i-H cn i-H o CJ o & (54) Title: HIGHLY EFFICIENT METHOD FOR ESTABLISHING ARTIFICIAL PLURIPOTENT STEM CELL (54) | (57) Abstract: The present invention provides method a for producing an iPS cell and a method for improving the efficiency of the establishment of an iPS cell, each of which involves a step of inducing (1) an episomal vector which carries a nuclear reprogram- ming factor and (2) an episomal vector which is different from the episomal vector (1) and carries EBNA-1 into somatic a cell. Also provided are: an iPS cell establishment efficiency-improving agent which comprises an episomal vector carrying a nucleic acid en - coding EBNA-1; and a kit for producing an iPS cell, which contains an episomal vector carrying nucleic a acid encoding a nuclear reprogramming factor. (57)®$: JiiT (D (1) (2) : (1) &%] L tz I t° V -<7 (2) (1) (tliEijco EBNA-1 try— iPSiMCOiiii^}^ EBNA-1 £ =1 — Ft & fell tELf=itfy—• uuKtZ— iPS tELf=itfy—• uuKtZ — iPSiMcDfFiiffl+y h t}If££*i-g>o
SG11201407917PA 2012-05-23 2013-05-23 Highly efficient method for establishing artificial pluripotent stem cell SG11201407917PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261650694P 2012-05-23 2012-05-23
PCT/JP2013/064409 WO2013176233A1 (en) 2012-05-23 2013-05-23 Highly efficient method for establishing artificial pluripotent stem cell

Publications (1)

Publication Number Publication Date
SG11201407917PA true SG11201407917PA (en) 2015-01-29

Family

ID=49623914

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407917PA SG11201407917PA (en) 2012-05-23 2013-05-23 Highly efficient method for establishing artificial pluripotent stem cell

Country Status (11)

Country Link
US (1) US10519425B2 (en)
EP (1) EP2853592B1 (en)
JP (1) JP6381442B2 (en)
KR (1) KR102066761B1 (en)
CN (1) CN104471060B (en)
AU (1) AU2013264708B2 (en)
CA (1) CA2874259C (en)
ES (1) ES2725827T3 (en)
HK (1) HK1208492A1 (en)
SG (1) SG11201407917PA (en)
WO (1) WO2013176233A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102625837B (en) 2009-08-07 2015-01-14 国立大学法人京都大学 Method of efficiently establishing induced pluripotent stem cells
WO2013176233A1 (en) 2012-05-23 2013-11-28 国立大学法人京都大学 Highly efficient method for establishing artificial pluripotent stem cell
US10738323B2 (en) 2013-07-12 2020-08-11 Cedars-Sinai Medical Center Generation of induced pluripotent stem cells from normal human mammary epithelial cells
CN103923920B (en) * 2014-04-04 2016-09-21 清华大学 A kind of strengthen the method for nonconformity gene expression in human cell
US20170211091A1 (en) * 2014-07-16 2017-07-27 Fundación Pública Andaluza Progreso Y Salud Methods for generating induced pluripotent stem cells
US20170226483A1 (en) * 2016-01-12 2017-08-10 Lonza Walkersville, Inc. Methods and Vectors to Produce Vector Free Induced Pluripotent Stem Cells
SG11201809279YA (en) 2016-04-22 2018-11-29 Univ Kyoto Method for producing dopamine-producing neural precursor cells
CN106086071B (en) * 2016-06-13 2019-08-09 广州市搏克生物技术有限公司 A kind of iPSCs of non-viral iPSCs abductive approach and its inducing composition, kit and its acquisition
CN105861447B (en) * 2016-06-13 2017-12-19 广州市搏克生物技术有限公司 A kind of non-viral iPSCs inducing compositions and its kit
US11572545B2 (en) 2016-06-16 2023-02-07 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
US10221395B2 (en) 2016-06-16 2019-03-05 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
CN106244558B (en) * 2016-08-31 2020-01-21 四川新生命干细胞科技股份有限公司 Method for reprogramming human mononuclear cells into induced pluripotent stem cells
JP2018082639A (en) * 2016-11-21 2018-05-31 学校法人千葉工業大学 Method for producing induced pluripotent stem cell from somatic cell, and medium for culturing induced pluripotent stem cell in undifferentiated state
AU2018333503A1 (en) * 2017-09-13 2020-02-27 BioNTech SE RNA replicon for reprogramming somatic cells
WO2020009714A1 (en) * 2018-07-02 2020-01-09 Lin Shi Lung In-Vitro Induction of Adult Stem Cell Expansion and Derivation
CN109913494A (en) * 2019-02-12 2019-06-21 北京呈诺医学科技有限公司 A kind of abductive approach of new ips cell
EP3957722A4 (en) * 2019-04-17 2023-01-18 Keio University Production method and kit of induced pluripotent stem cells
CN114645023B (en) * 2022-05-18 2022-09-20 上海爱萨尔生物科技有限公司 System and method for reprogramming peripheral blood mononuclear cells to induced pluripotent stem cells

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
EP1859026A2 (en) 2005-01-31 2007-11-28 ES Cell International Pte Ltd. Directed differentiation of embryonic stem cells and uses thereof
EP2206724A1 (en) 2005-12-13 2010-07-14 Kyoto University Nuclear reprogramming factor
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
WO2007080590A2 (en) 2006-01-11 2007-07-19 Technion Research & Development Foundation Ltd. Human embryonic stem cell-derived connective tissue progenitors for tissue engineering
SG193652A1 (en) 2007-03-23 2013-10-30 Wisconsin Alumni Res Found Somatic cell reprogramming
WO2008144580A2 (en) 2007-05-17 2008-11-27 Oregon Health & Science University Primate stem cells produced by somatic cell nuclear transfer
WO2009057831A1 (en) 2007-10-31 2009-05-07 Kyoto University Nuclear reprogramming method
JP5558097B2 (en) 2007-12-10 2014-07-23 国立大学法人京都大学 Efficient nuclear initialization method
EP2268796A1 (en) 2008-03-17 2011-01-05 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination
CN101550406B (en) 2008-04-03 2016-02-10 北京大学 Prepare the method for pluripotent stem cell, test kit and purposes
DK2297307T3 (en) 2008-06-04 2016-07-25 Cellular Dynamics Int Inc PROCEDURES FOR THE MANUFACTURE OF IPS CELLS USING NON-VIRAL METHODS
CN101835890B (en) 2008-06-27 2013-07-24 国立大学法人京都大学 Method of efficiently establishing induced pluripotent stem cells
EP2307539B1 (en) 2008-07-30 2014-11-19 Kyoto University Method of efficiently establishing induced pluripotent stem cells
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
JP2010273680A (en) * 2009-05-29 2010-12-09 Kyoto Univ Method for preparing induced pluripotent stem cell wherein reprogramming factor is eliminated
CN102625837B (en) 2009-08-07 2015-01-14 国立大学法人京都大学 Method of efficiently establishing induced pluripotent stem cells
US9719146B2 (en) * 2009-09-09 2017-08-01 General Electric Company Composition and method for imaging stem cells
WO2011032166A2 (en) 2009-09-14 2011-03-17 The Johns Hopkins University Reprogramming blood cells to pluripotent and multipotent stem cells
CA2789749C (en) 2010-02-16 2018-09-04 Kyoto University Method of efficiently establishing induced pluripotent stem cells
WO2011119942A1 (en) * 2010-03-25 2011-09-29 Vistagen Therapeutics, Inc. Induction of ips cells using transient episomal vectors
CA2806858C (en) * 2010-08-04 2021-06-15 Cellular Dynamics International, Inc. Reprogramming immortalized b cells
WO2013022022A1 (en) * 2011-08-08 2013-02-14 国立大学法人京都大学 Method for efficient establishment of artificial pluripotent stem cells
WO2013176233A1 (en) 2012-05-23 2013-11-28 国立大学法人京都大学 Highly efficient method for establishing artificial pluripotent stem cell

Also Published As

Publication number Publication date
CA2874259C (en) 2021-02-09
AU2013264708A1 (en) 2015-01-15
CN104471060B (en) 2021-11-05
JPWO2013176233A1 (en) 2016-01-14
EP2853592B1 (en) 2019-02-20
CA2874259A1 (en) 2013-11-28
JP6381442B2 (en) 2018-08-29
US10519425B2 (en) 2019-12-31
EP2853592A1 (en) 2015-04-01
ES2725827T3 (en) 2019-09-27
WO2013176233A1 (en) 2013-11-28
KR20150014512A (en) 2015-02-06
US20150175973A1 (en) 2015-06-25
AU2013264708B2 (en) 2019-03-07
KR102066761B1 (en) 2020-01-15
EP2853592A4 (en) 2016-01-13
HK1208492A1 (en) 2016-03-04
CN104471060A (en) 2015-03-25

Similar Documents

Publication Publication Date Title
SG11201407917PA (en) Highly efficient method for establishing artificial pluripotent stem cell
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201803593QA (en) Engineered nucleic-acid targeting nucleic acids
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201804070XA (en) Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
SG11201407117TA (en) Composition for repairing cartilage tissue, method for producing same, and use thereof
SG11201811048UA (en) Single-cell transcript sequencing
SG11201803900UA (en) Process for preparing polyurea microcapsules with improved deposition
SG11201810286WA (en) Variable diameter bioreactors
SG11201408589RA (en) Encoding device and encoding method
SG11201408303WA (en) Adhesive compositions of propylene-based and ethylene-based polymers
SG11201402746TA (en) Electronic substrate housing equipment and electric apparatus
SG11201408405WA (en) Engineered three-dimensional connective tissue constructs and methods of making the same
SG11201408024TA (en) Method for obtaining monocytes or nk cells
SG11201903287PA (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
SG11201408017VA (en) Interaction prediction device, interaction prediction method, and computer program product
SG11201903329WA (en) Method for preparing electrocompetent yeast cells, and method for using said cells
SG11201810143PA (en) Exon skipping oligomers for muscular dystrophy
SG11201407844SA (en) Smoking agent and smoking device
SG11201408502XA (en) Method of purifying an antibody
SG11201804856VA (en) C-terminal lysine conjugated immunoglobulins
SG11201903230QA (en) TCRa HOMING ENDONUCLEASE VARIANTS
SG11201805061YA (en) Crystalline form of gemcitabine
SG11201407570SA (en) Surface covering system and method for producing such a system